GlassScriptPhysician profile
A Lynn Womack
NPI 1881609683
$1,605.41
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $405 · 2021: $312.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $565.42 | 2019-2021 | |
| Pfizer INC. | $254.52 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $149.00 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $138.85 | 2019 | |
| Allergan, INC. | $74.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $70.38 | 2019 | |
| Abbvie INC. | $65.53 | 2021 | |
| Amgen INC. | $48.09 | 2019 | |
| Novo Nordisk INC | $40.85 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.02 | 2019 | |
| Merck Sharp & Dohme LLC | $28.88 | 2019-2020 | |
| Amarin Pharma, INC. | $28.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.46 | 2019-2020 | |
| Genentech USA, INC. | $19.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.92 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.54 | 2019 | |
| Shire North American Group INC | $12.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw A Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.